table of contents
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
It can be confusing to hear you’re getting an off-label medication. When a healthcare provider prescribes a medication or treatment off-label, it doesn’t mean they’re going rogue.
Licensed clinicians are permitted to use their professional judgment to prescribe drugs off-label if they feel it’s the best treatment for patients. It might sound like something is prescribed “under the table,” but off-label prescriptions are actually quite common. In some cases, they’re even the best treatment option.
Men’s healthcare, without the waiting room
Connect with a US-licensed healthcare provider about ED, premature ejaculation, hair loss, and more.
What does off-label mean?
Before we dig in, let’s define what we mean by off-label. Before prescription drugs are introduced to the general public, they’re tested in clinical trials to make sure that they’re safe. These trials also test to make sure the medication is effective at treating the condition it’s being evaluated to treat.
Researchers collect scientific evidence and set up guidelines for each new drug, and then the U.S. Food and Drug Administration (FDA) evaluates the data. It’s a complex process that can take years, but once a drug is approved for a given use, it’s considered to be on-label.
During the study phase, researchers may observe a medication is helpful for more than just the intended condition. Although it’s not what the medication was initially approved for, your provider may prescribe it anyway.
For example, the drug prazosin is approved to treat high blood pressure but has also been found to be effective for PTSD-related nightmares. This is called off-label prescribing (Koola, 2014).
The medication terbutaline is most typically prescribed to treat asthma, but clinicians have found it’s also effective at stopping uterine contractions during labor. And while the FDA has never granted drug approval for this use, it’s standard practice to use it to stop premature labor.
If you’re given medication off-label, it doesn’t mean it’s illegal, nor are you becoming part of some unknown experiment. There are plenty of good reasons for prescribing off-label that we’ll get into below.
Why use an off-label drug?
There are so many medications available for seemingly every condition––so why would a healthcare provider prescribe something off-label? Here are some of the most common reasons.
No known treatment for a disease
New diseases need new solutions, but it takes time to develop and test them. For example, in 2019 COVID-19 was a brand new disease. No previous trials identified effective medications or guidelines on how to manage severe cases. On top of that, it would likely take months or even years to test and get approval for new treatments.
Because of this, healthcare experts turned to other treatments already FDA-approved for treating other similar viruses. Since the therapies were already tested and deemed safe, they made good candidates as off-label drugs to treat COVID (WHO, 2020).
Off-label drug prescribing is common when it comes to the treatment of rare diseases for the same reasons.
Amitriptyline for sleep: a common off-label use
When a study can’t be done to evaluate the effectiveness of a medication
There is much more scientific evidence available about medications for adults than children.
One reason for that is that it can be difficult to enroll children in clinical trials from an ethical perspective. Consent is an important part of participating in clinical studies and it’s not something children can provide.
Our biology is also different at different stages of life (especially during childhood), making the establishment of pediatric guidelines problematic. For these reasons, medications with labeled uses in adults are often used off-label to treat the same conditions in children.
For example, the drug morphine is FDA-approved for pain relief and often administered after surgery. Children also frequently receive this medication for pain, but in kids, the use is typically considered to be off-label since it hasn’t been approved for this age group (Shah, 2007).
In the case of terbutaline mentioned previously, there’s no ethical way to do a study comparing the effectiveness of a drug that stops preterm labor to a placebo since an ineffective medication might risk the life of the baby, mother, or both.
For that reason, healthcare providers will continue to use the drug off-label and it won’t receive FDA approval despite plenty of research demonstrating its effectiveness.
When other approved treatment methods have failed
Off-label prescribing is very common in cancer treatment. Sometimes people are initially treated with an FDA-approved medication. However, not every medication works for everyone. When this happens, a healthcare provider may use a different medication off-label.
Off-label prescribing is used in up to one-third of people with metastatic cancer ( cancer that has spread to other areas of the body) and people receiving palliative care, which is care meant to make them more comfortable but will not cure their disease (Saiyed, 2017).
One small study found that 34% of cancer patients who received off-label treatments reported clinical benefits (van der Velden, 2019). Cancer is actually many different diseases, and each form has different symptoms and characteristics, so the results of these off-label cancer treatments can vary from person to person.
How to safely store medication and prescription drugs
Similar treatments have been approved
Off-label prescribing is common in the treatment of mental health conditions. Many mental healthcare professionals prescribe off-label antipsychotic, antidepressant, and attention deficit hyperactivity disorder (ADHD) drugs, though the off-label drugs they prescribe are often in the same drug class as the FDA-approved ones.
You might think swapping out one drug for another isn’t the best idea, but medications in the same class frequently have similar or even identical effects on the body. These drugs also share similar side effects, so healthcare providers are often comfortable substituting on-label drugs with off-label ones.
For example, the selective serotonin reuptake inhibitor (SSRI) escitalopram (brand name Lexapro; see Important Safety Information) is FDA-approved to treat anxiety but is also used off-label to treat eating disorders and obsessive-compulsive disorder (OCD).
Another drug in this class is citalopram (also known as Celexa), which is often used off-label for anxiety even though it’s not labeled for that purpose (Vijay, 2018). Providers can also take the liberty of choosing an off-label equivalent if it is covered by insurance when the on-label drug isn’t.
What are the disadvantages of prescribing off-label?
Proper prescribing of off-label medication relies on the expertise of an experienced healthcare provider who is familiar with the medication and the condition being treated and is aware of any potential complications or interactions that might arise.
Sometimes, off-label use opens doors for new uses and indications for existing medications. But because the FDA doesn’t regulate this process, healthcare providers must use their best judgment in advising patients on what to take.
If you’ve been prescribed a medication off-label, you can ask your provider or pharmacist about the reason behind choosing the treatment to better understand your health.
- American Cancer Society (ACS). (2015). Off-label Drug Use. Retrieved from https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/off-label-drug-use.html
- Aronson, J. K. & Ferner, R. E. (2017). Unlicensed and off-label uses of medicines: definitions and clarification of terminology. British Journal of Clinical Pharmacology, 83(12), 2615–2625. doi: 10.1111/bcp.13394. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28779556/
- Dooms, M. & Killick, J. (2017). Off-label use of medicines: The need for good practice guidelines. The International Journal of Risk & Safety in Medicine, 29(1-2), 17–23. doi: 10.3233/JRS-170737. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28885218/
- Frattarelli, D. A., Galinkin, J. L., Green, T. P., et al. (2014). Off-label use of drugs in children. Pediatrics, 133(3), 563–567. doi: 10.1542/peds.2013-4060. Retrieved from https://pubmed.ncbi.nlm.nih.gov/24567009/
- Goločorbin Kon, S., Iliković, I., & Mikov, M. (2015). Reasons for and frequency of off-label drug use. Medicinski Pregled, 68(1-2), 35–40. doi: 10.2298/mpns1502035g. Retrieved from https://pubmed.ncbi.nlm.nih.gov/26012242/
- Guenther, L., Lynde, C., & Poulin, Y. (2019). Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders. Journal of Cutaneous Medicine and Surgery, 23(4), 27S–34S. doi: 10.1177/1203475419857668. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31476936/
- Kimland, E. & Odlind, V. (2012). Off-label drug use in pediatric patients. Clinical Pharmacology and Therapeutics, 91(5), 796–801. doi: 10.1038/clpt.2012.26. Retrieved from https://pubmed.ncbi.nlm.nih.gov/22472984/
- Oshikoya, K. A., Wharton, G. T., Avant, D., et al. (2019). Serious Adverse Events Associated with Off-Label Use of Azithromycin or Fentanyl in Children in Intensive Care Units: A Retrospective Chart Review. Pediatric Drugs, 21(1), 47–58. doi: 10.1007/s40272-018-0318-9. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30484072/
- Paumgartten, F. & Oliveira, A. (2020). Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Ciencia & Saude Coletiva, 25(9), 3413–3419. doi: 10.1590/1413-81232020259.16792020. Retrieved from https://pubmed.ncbi.nlm.nih.gov/32876249/
- Pratico, A. D., Longo, L., Mansueto, S., et al. (2018). Off-Label Use of Drugs and Adverse Drug Reactions in Pediatric Units: A Prospective, Multicenter Study. Current Drug Safety, 13(3), 200–207. doi: 10.2174/1574886313666180619120406. Retrieved from https://pubmed.ncbi.nlm.nih.gov/29921210/
- Saiyed, M. M., Ong, P. S., & Chew, L. (2017). Off-label drug use in oncology: a systematic review of literature. Journal of Clinical Pharmacy and Therapeutics, 42(3), 251–258. doi: 10.1111/jcpt.12507. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28164359/
- Shah, S. S., Hall, M., Goodman, D. M., et al. (2007). Off-label drug use in hospitalized children. Archives of Pediatrics & Adolescent Medicine, 161(3), 282–290. doi:10.1001/archpedi.161.3.282. Retrieved from https://pubmed.ncbi.nlm.nih.gov/17339510/
- U.S. Food and Drug Administration (FDA). (1998). ‘Off-Label’’ and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices. Retrieved on Aug. 31, 2021 from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/label-and-investigational-use-marketed-drugs-biologics-and-medical-devices
- U.S. Food and Drug Administration (FDA). (2018). Understanding Unapproved Use of Approved Drugs ‘Off Label.’ Retrieved on Sep. 23, 2021 from https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
- U.S. Food and Drug Administration (FDA). (2021). Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. Retrieved on Sep. 23, 2021 from https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19
- van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., et al. (2019). The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature, 574(7776), 127–131. doi: 10.1038/s41586-019-1600-x. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31570881/
- Wittich, C. M., Burkle, C. M., & Lanier, W. L. (2012). Ten common questions (and their answers) about off-label drug use. Mayo Clinic Proceedings, 87(10), 982–990. doi: 10.1016/j.mayocp.2012.04.017. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538391/
- Wong, J., Motulsky, A., Abrahamowicz, M., Eguale, et al. (2017). Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ, 356, j603. doi: 10.1136/bmj.j603. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28228380/
- World Health Organization (WHO). (2020). Off-label use of medicines for COVID-19. Retrieved Sep. 1, 2021 from https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-covid-19